Cargando…
Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
A network meta-analysis evaluating efficacy and adverse events of eight erlotinib-based therapies (erlotinib+placebo, erlotinib+tivantinib, erlotinib+celecoxib, erlotinib+onartuzumab, erlotinib+sunitinib, erlotinib+entinostat, erlotinib+sorafenib, and erlotinib+bevacizumab) for advanced/metastatic n...
Autores principales: | Li, Fei, Zhang, Shu-Hua, Pang, Li-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689727/ https://www.ncbi.nlm.nih.gov/pubmed/29156837 http://dx.doi.org/10.18632/oncotarget.19735 |
Ejemplares similares
-
Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer
por: Wu, Jing, et al.
Publicado: (2017) -
Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017) -
Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
por: Pei, Wen-Guang, et al.
Publicado: (2023) -
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
por: Li, Yan, et al.
Publicado: (2023) -
The incidence and relative risk of adverse events in patients treated
with bisphosphonate therapy for breast cancer: a systematic review and
meta-analysis
por: Yang, Yan-Li, et al.
Publicado: (2019)